COMPASS Pathways (CMPS) Competitors $3.02 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.00 -0.02 (-0.70%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPS vs. SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, CMRX, CDMO, and RCUSShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Arcus Biosciences Syndax Pharmaceuticals (NASDAQ:SNDX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Is SNDX or CMPS more profitable? COMPASS Pathways' return on equity of -63.85% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% COMPASS Pathways N/A -63.85%-51.97% Does the MarketBeat Community favor SNDX or CMPS? Syndax Pharmaceuticals received 325 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 81.48% of users gave COMPASS Pathways an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% COMPASS PathwaysOutperform Votes6681.48% Underperform Votes1518.52% Does the media prefer SNDX or CMPS? In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than COMPASS Pathways. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 2 mentions for COMPASS Pathways. Syndax Pharmaceuticals' average media sentiment score of 1.01 beat COMPASS Pathways' score of 0.94 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SNDX or CMPS? Syndax Pharmaceuticals presently has a consensus target price of $36.20, indicating a potential upside of 219.51%. COMPASS Pathways has a consensus target price of $20.20, indicating a potential upside of 568.87%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, SNDX or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M41.17-$209.36M-$3.73-3.04COMPASS PathwaysN/AN/A-$118.46M-$2.30-1.31 Which has more volatility & risk, SNDX or CMPS? Syndax Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Do insiders & institutionals believe in SNDX or CMPS? 46.2% of COMPASS Pathways shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCOMPASS Pathways beats Syndax Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Remove Ads Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.87M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-1.376.7921.7317.81Price / SalesN/A225.93379.1494.58Price / CashN/A65.6738.1534.64Price / Book0.835.866.464.00Net Income-$118.46M$141.86M$3.20B$247.23M7 Day Performance13.53%8.98%6.54%7.26%1 Month Performance-13.22%-12.65%-8.55%-6.26%1 Year Performance-63.70%-11.99%10.33%-0.18% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways3.2464 of 5 stars$3.02flat$20.20+568.9%-65.1%$279.87MN/A-1.37120SNDXSyndax Pharmaceuticals3.4858 of 5 stars$10.99-2.3%$36.20+229.3%-48.3%$945.88M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1802 of 5 stars$5.78-4.2%$22.60+291.3%+3.4%$890.37M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.1648 of 5 stars$27.37-2.7%$43.60+59.3%-25.1%$879.58M$631.45M11.80210News CoveragePositive NewsGap DownELVNEnliven Therapeutics2.5509 of 5 stars$17.82-4.7%$38.75+117.5%-18.5%$873.06MN/A-9.3850News CoverageDYNDyne Therapeutics3.73 of 5 stars$7.48-9.6%$47.46+534.3%-71.1%$846.37MN/A-2.10100Positive NewsGPCRStructure Therapeutics2.5699 of 5 stars$14.33-5.2%$81.29+467.4%-51.8%$821.55MN/A-19.36136News CoverageETNB89bio2.5806 of 5 stars$5.48-5.1%$27.56+403.3%-39.7%$804.81MN/A-1.8940Short Interest ↑News CoverageGap DownCMRXChimerix2.9137 of 5 stars$8.53-0.1%$8.53+0.1%+788.9%$799.68M$212,000.00-9.0790CDMOAvid Bioservices0.7921 of 5 stars$12.50+0.1%$12.25-2.0%+85.4%$799.18M$139.91M-5.23320High Trading VolumeRCUSArcus Biosciences2.4548 of 5 stars$7.28+5.9%$30.25+315.8%-53.7%$768.03M$258M-2.32500 Remove Ads Related Companies and Tools Related Companies SNDX Competitors WVE Competitors COLL Competitors ELVN Competitors DYN Competitors GPCR Competitors ETNB Competitors CMRX Competitors CDMO Competitors RCUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMPS Stock Free CMPS Stock Alerts